AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of ...

Astrazeneca has defended the £14.7 million pay package handed to chief executive Pascal Soriot, saying the group is too big ...

The CDC's Advisory Committee on Immunization Practices was set to meet beginning February 26 and provide recommendations ...

(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...

Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with ...

Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

London's exporter-heavy FTSE 100 index closed at a record high on Wednesday, lifted by gains in AstraZeneca and insurer Prudential, with a weak pound providing an additional boost. U.S. stock ...

Charles River expanded the Memphis facility in November 2022, adding nine processing suites to its 16 clean rooms at the site ...

Maria joined AstraZeneca in 2017 as head of Respiratory, Inflammation & Autoimmunity in the Innovative Medicines and Early Development (IMED) Biotech Unit. In her role she leads early-stage ...

Non-U.S. developed markets stocks finished the fourth quarter lower. Political uncertainty in some of the largest European ...